CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $1.23 billion. The enterprise value is $779.06 million.
Important Dates
The last earnings date was Monday, November 24, 2025, before market open.
| Earnings Date | Nov 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 225.18 million shares outstanding. The number of shares has decreased by -38.70% in one year.
| Current Share Class | 225.18M |
| Shares Outstanding | 225.18M |
| Shares Change (YoY) | -38.70% |
| Shares Change (QoQ) | -21.60% |
| Owned by Insiders (%) | 5.56% |
| Owned by Institutions (%) | 22.25% |
| Float | 125.88M |
Valuation Ratios
The trailing PE ratio is 5.85.
| PE Ratio | 5.85 |
| Forward PE | n/a |
| PS Ratio | 10.22 |
| Forward PS | 36.51 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 5.15 |
| EV / Sales | 9.39 |
| EV / EBITDA | 3.43 |
| EV / EBIT | 3.65 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.70 |
| Quick Ratio | 1.88 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | n/a |
| Interest Coverage | 29.46 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 20.18% |
| Revenue Per Employee | $84,436 |
| Profits Per Employee | $153,763 |
| Employee Count | 983 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CureVac has paid $33.52 million in taxes.
| Income Tax | 33.52M |
| Effective Tax Rate | 18.15% |
Stock Price Statistics
The stock price has increased by +97.83% in the last 52 weeks. The beta is 1.78, so CureVac's price volatility has been higher than the market average.
| Beta (5Y) | 1.78 |
| 52-Week Price Change | +97.83% |
| 50-Day Moving Average | 5.33 |
| 200-Day Moving Average | 4.57 |
| Relative Strength Index (RSI) | 63.17 |
| Average Volume (20 Days) | 1,091,780 |
Short Selling Information
The latest short interest is 801,715, so 0.36% of the outstanding shares have been sold short.
| Short Interest | 801,715 |
| Short Previous Month | 927,476 |
| Short % of Shares Out | 0.36% |
| Short % of Float | 0.64% |
| Short Ratio (days to cover) | 1.79 |
Income Statement
In the last 12 months, CureVac had revenue of $83.00 million and earned $151.15 million in profits. Earnings per share was $0.94.
| Revenue | 83.00M |
| Gross Profit | 77.43M |
| Operating Income | 213.63M |
| Pretax Income | 184.67M |
| Net Income | 151.15M |
| EBITDA | 227.26M |
| EBIT | 213.63M |
| Earnings Per Share (EPS) | $0.94 |
Full Income StatementBalance Sheet
The company has $488.20 million in cash and $41.14 million in debt, giving a net cash position of $447.05 million or $1.99 per share.
| Cash & Cash Equivalents | 488.20M |
| Total Debt | 41.14M |
| Net Cash | 447.05M |
| Net Cash Per Share | $1.99 |
| Equity (Book Value) | 1.02B |
| Book Value Per Share | 5.65 |
| Working Capital | 747.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$140.96 million and capital expenditures -$4.68 million, giving a free cash flow of -$143.90 million.
| Operating Cash Flow | -140.96M |
| Capital Expenditures | -4.68M |
| Free Cash Flow | -143.90M |
| FCF Per Share | -$0.64 |
Full Cash Flow StatementMargins
Gross margin is 93.29%, with operating and profit margins of 257.38% and 182.11%.
| Gross Margin | 93.29% |
| Operating Margin | 257.38% |
| Pretax Margin | 222.50% |
| Profit Margin | 182.11% |
| EBITDA Margin | 273.81% |
| EBIT Margin | 257.38% |
| FCF Margin | n/a |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 38.70% |
| Shareholder Yield | 38.70% |
| Earnings Yield | 12.33% |
| FCF Yield | -11.74% |
Dividend DetailsAnalyst Forecast
The average price target for CureVac is $6.83, which is 24.64% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.83 |
| Price Target Difference | 24.64% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -13.60% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of 1.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.52 |
| Piotroski F-Score | 2 |
